iBio, Inc. (NYSEAMERICAN:IBIO) Short Interest Down 12.2% in November

iBio, Inc. (NYSEAMERICAN:IBIO) saw a significant decline in short interest during the month of November. As of November 30th, there was short interest totalling 202,800 shares, a decline of 12.2% from the November 15th total of 230,900 shares. Approximately 2.2% of the company’s stock are sold short. Based on an average trading volume of 135,900 shares, the days-to-cover ratio is currently 1.5 days.

iBio Trading Down 0.9 %

IBIO stock traded down $0.02 during midday trading on Tuesday, reaching $2.33. 65,547 shares of the company were exchanged, compared to its average volume of 1,084,605. The company has a debt-to-equity ratio of 0.04, a current ratio of 0.91 and a quick ratio of 0.91. iBio has a 1-year low of $1.02 and a 1-year high of $4.98.

iBio Company Profile

iBio, Inc, a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.